Skip to main content
IMMUPHARMA PLC logo

IMMUPHARMA PLC — Investor Relations & Filings

Ticker · IMM ISIN · GB0033711010 LEI · 213800VZKGHXC7VUS895 IL Professional, scientific and technical activities
Open in API
Filings indexed 443 across all filing types
Latest filing 2015-11-30 Director's Dealing
Country GB United Kingdom
Listing IL IMM

About IMMUPHARMA PLC

https://www.immupharma.co.uk/

ImmuPharma PLC is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The company's primary focus is on creating novel treatments for serious medical conditions with significant unmet needs. Its core activities involve advancing a pipeline of drug candidates through research and various stages of clinical development, leveraging its expertise in peptide technology.

Recent filings

Filing Released Lang Actions
Holding(s) in Company
Director's Dealing Classification · 1% confidence The document is explicitly labeled with "RNS Number : 3784H" and contains the header "TR-1 NOTIFICATION OF MAJOR INTEREST IN SHARES BY AVIVA". TR-1 notifications are regulatory filings used in the UK/EU to report significant changes in share ownership (major interests). While this concerns shareholding changes (which might suggest MRQ), the format and explicit reference to RNS (Regulatory News Service) strongly indicate this is a standard regulatory disclosure. Since 'Major Shareholding Notification' (MRQ) is defined as notification of changes in significant share ownership levels, and this document is a TR-1 detailing exactly that, MRQ is the most specific fit. RNS is the fallback, but MRQ is better aligned with the content.
2015-11-30 English
Lupuzor Phase III Pivotal Trial Update
Regulatory Filings Classification · 1% confidence The document begins with an 'RNS Number' and the date, followed by 'FOR IMMEDIATE RELEASE'. The content provides a detailed update on the progress of a clinical trial (Lupuzor Phase III trial update) for a pharmaceutical company (ImmuPharma PLC). This type of announcement, which disseminates material, time-sensitive information to the market via an official channel like RNS (Regulatory News Service, associated with the London Stock Exchange), fits best under the general 'Regulatory Filings' category, as it is not a specific financial report (10-K, IR, ER) or a management/governance document. Since it is a formal, non-standardized announcement disseminated through the official regulatory news service, RNS is the most appropriate classification.
2015-11-04 English
Lupuzor Phase III Pivotal Trial Update
Regulatory Filings Classification · 1% confidence The document is identified by the 'RNS Number' header and the concluding statement 'This information is provided by RNS The company news service from the London Stock Exchange'. The content is a press release providing an update on the progress of a Phase III clinical trial for a drug called Lupuzor. This type of announcement, which is a formal update on operational or regulatory progress disseminated via a regulatory news service, fits best under the general 'Regulatory Filings' category, as it is not a full financial report (10-K, IR), an earnings release (ER), a management discussion (MDA), or a specific legal/director/dividend notice. It is a general corporate update disseminated through the regulatory channel.
2015-11-04 English
Directorate Change
Board/Management Information Classification · 1% confidence The document is very short (1586 characters) and announces a specific corporate event: 'Ajay Agrawal has stepped down as Non-Executive Director with immediate effect.' This directly relates to changes in the company's board of directors or senior management. This aligns perfectly with the definition for Board/Management Information (MANG). Although it carries an RNS Number, the content is specific enough to classify it as MANG rather than the general fallback RNS.
2015-10-23 English
Directorate Change
Board/Management Information Classification · 1% confidence The document is an RNS announcement (RNS Number : 6273A) from ImmuPharma PLC, dated 30 September 2015. The core content announces the appointment of Tim McCarthy as Non-executive Chairman. This type of announcement, detailing changes in senior management or the board of directors, directly corresponds to the definition for Board/Management Information (MANG). Although it is distributed via RNS, the specific subject matter is management change, making MANG the most precise classification over the general RNS fallback.
2015-09-30 English
Interim Results
Interim / Quarterly Report Classification · 1% confidence The document is an 'Interim Results Announcement' for ImmuPharma PLC for the six months ended 30 June 2015. It contains detailed financial highlights, a management review, and a statement from the directors. It also includes an 'Independent Review Report' section, which is characteristic of an interim financial report. Since it provides substantive financial data and analysis for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. H1 2015
2015-09-30 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.